23:46 , Aug 17, 2017 |  BC Week In Review  |  Clinical News

Cyclacel reports Phase I data for CDK2/9 inhibitor in solid tumors

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) reported data from 24 heavily treated patients with advanced solid tumors in the dose-escalation part 1 of a Phase I trial showing that 8-288 mg/m 2 /day doses of CYC065 given...
01:35 , Aug 11, 2017 |  BC Innovations  |  Tools & Techniques

K follows C in chemoproteomics

A year after publishing a map of druggable cysteines in the proteome, Ben Cravatt’s lab at Scripps has reported its chemoproteomics tools can also profile lysines. By identifying reactive lysines in dozens of proteins for...
15:45 , Apr 13, 2017 |  BC Week In Review  |  Clinical News

CYC065: Preclinical data

In vitro , CYC065 inhibited growth, triggered apoptosis and induced anaphase catastrophe in murine and human lung cancer cells with known high metastatic potential. CYC065 also inhibited migration and invasion of lung cancer cells. Data...
23:25 , Feb 23, 2017 |  BC Extra  |  Clinical News

Cyclacel's sapacitabine fails in Phase III AML trial

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) lost $1.36 (25%) to $4.05 on Thursday after its sapacitabine ( CYC682 ) missed the primary endpoint in the pivotal Phase III SEAMLESS trial to treat newly diagnosed acute myelogenous leukemia...
01:10 , Dec 7, 2016 |  BC Extra  |  Clinical News

GNS identifies disease drivers from CoMMpass data

GNS Healthcare Inc. (Cambridge, Mass.) said it has identified four genes as "top drivers" of high-risk multiple myeloma. Using its machine learning technology, the company is collaborating with the Multiple Myeloma Research Foundation (MMRF) to...
07:00 , Aug 18, 2016 |  BC Innovations  |  Translation in Brief

The CDK5 checkpoint

Despite the clinical success of checkpoint inhibitors, immuno-oncologists still have an incomplete understanding of how the receptors and their ligands prevent antitumor immunity. In a new study, Case Western Reserve University researchers found mechanistic data...
08:00 , Dec 14, 2015 |  BioCentury  |  Product Development

Following CoMMpass

Amidst a flood of promising data for hot targets, indications and technologies at this year's American Society of Hematology meeting, one collection of presentations stands out not only for the wide-reaching implications of their data,...
08:00 , Nov 16, 2015 |  BC Week In Review  |  Clinical News

CYC065: Phase I started

Cyclacel began an open-label, dose-escalation, U.S. Phase I trial to evaluate oral CYC065 every 3 weeks in about 35 patients. Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC), Berkeley Heights, N.J.   Product: CYC065   Business: Cancer   Molecular...
07:00 , Oct 1, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Cyclin dependent kinase 1 (CDK1; CDC2); CDK2; centrosomal protein 290kDa (CEP290)

Renal disease INDICATION: Renal failure In vitro and mouse studies suggest inhibiting CDK1 and CDK2 could help treat Joubert syndrome cases caused by loss-of-function mutations in CEP290 . Levels of CDK1 and CDK2 were higher...
07:00 , Jul 24, 2014 |  BC Innovations  |  Targets & Mechanisms

Selecting CDK7

Selective inhibitors of cyclin dependent kinase s have been hard to develop because the active sites of many family members are so similar. Now, a Harvard Medical School team has found a cyclin dependent kinase...